OCOscar Calzada

Oscar Calzada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Oscar Calzada has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Microwave-assisted reversible addition–fragmentation chain transfer polymerization of cationic monomers in mixed aqueous solvents

    by Jonathan Tran, Alexander Prossnitz, William Sherwin, Sydney Mikulec, Amanda Ennis, Alisson Magsumbol, Alexandra Jameson, Joan Schellinger, Oscar Calzada

  • Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma

    by Brian T. Hill, Loretta Nastoupil, Allison M. Winter, Melody R. Becnel, James R. Cerhan, Thomas M. Habermann, Brian K. Link, Matthew J. Maurer, Bita Fakhri, Prathima Reddy, et al.

    Summary: Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation for FL, resulting in disparate practice patterns. Prospective trials have shown benefit of MR after R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or R‐CVP (rituximab, cyclophosphamide, vincristine, prednisone), yet recent data from the GALLIUM study comparing outcomes of patients treated with chemotherapy with R or obinutuzumab (G) showed higher than anticipated fatal adverse events with BR/BG. In order to assess the efficacy and tolerability of MR after BR, we retrospectively collected data on 640 newly diagnosed patients treated with FL. We found that patients who achieved partial remission (PR) after ≥4 cycles of BR had improved duration of response (DOR) with MR vs. no maintenance, whereas those in complete remission did not. These findings were confirmed in a validation cohort. In the entire study population, the known fatal adverse event rate after BR was 2·5% and did not significantly differ in those receiving MR versus no maintenance. [Correction added on 14 January 2019, after online publication: The preceding sentence has been corrected in this current version.] Within the limitations inherent to retrospective analysis, these data suggest that FL patients with a PR to BR experience prolongation of remission with MR with an acceptable safety profile.


  • Open Access

    R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis

    by Nirav N. Shah, Aniko Szabo, Scott F. Huntington, Narendranath Epperla, Nishitha Reddy, Siddhartha Ganguly, Julie Vose, Cynthia Obiozor, Fahad Faruqi, Alexandra E. Kovach, et al.

    Summary: Primary mediastinal (thymic) large B‐cell lymphoma (PMBCL) is an uncommon subtype of non‐Hodgkin lymphoma (NHL) that presents with a mediastinal mass and has unique clinicopathological features. Historically, patients with PMBCL were treated with R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy ± involved field radiation. Since a phase II trial, published in April 2013, demonstrated excellent results using dose‐adjusted (DA) R‐EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), this treatment has gained popularity. We performed a retrospective, multicentre analysis of patients aged ≥18 years with PMBCL since January 2011. Patients were stratified by frontline regimen, R‐CHOP versus DA‐R‐EPOCH. 132 patients were identified from 11 contributing centres (56 R‐CHOP and 76 DA‐R‐EPOCH). The primary outcome was overall survival. Secondary outcomes included progression‐free survival, complete response (CR) rate, and rates of treatment‐related complications. Demographic characteristics were similar in both groups. DA‐R‐EPOCH use increased after April 2013 (79% vs. 45%, P < 0·001), and there was less radiation use after DA‐R‐EPOCH (13% vs. 59%, P < 0·001). While CR rates were higher with DA‐R‐EPOCH (84% vs. 70%, P = 0·046), these patients were more likely to experience treatment‐related toxicities. At 2 years, 89% of R‐CHOP patients and 91% of DA‐R‐EPOCH patients were alive. To our knowledge, this represents the largest series comparing outcomes of R‐CHOP to DA‐R‐EPOCH for PMBCL.


  • Open Access

    Prolonged Progression-Free Survival Is Possible in Patients with Diffuse Large B-Cell Lymphoma Receiving > 1 Salvage Therapies before Autologous Stem Cell Transplant

    by Abigail G Kettle, Jeffrey Switchenko, Oscar Calzada, Anh Thuy Phan, Monique Farone, Michael Graiser, Christopher R. Flowers, Jonathon B. Cohen

    Introduction While 50-60% of patients with diffuse large B-cell lymphoma (DLBCL) are cured with initial chemoimmunotherapy such as R-CHOP, many patients will relapse and require additional therapy. Historically, autologous stem cell transplant (ASCT) has been utilized in chemo-sensitive patients with relapsed DLBCL although the role of ASCT in patients who require > 1 salvage treatment to achieve remission is less defined due to concerns about the likelihood of long-term remission in that population. We evaluated the outcome of ASCT in patients who required >1 salvage therapy. Methods We included all patients undergoing ASCT for relapsed/refractory DLBCL at our site between 2005-2016 who received > 1 salvage treatment before transplant, with radiation therapy considered a salvage treatment if given after relapse but before ASCT. We collected demographic, clinical, laboratory and pathologic data on all patients. We defined progression-free survival (PFS) as time from ASCT to date of progression or death from any cause and overall survival (OS) as time from ASCT to date of death from any cause. Living patients were censored at the time of their last follow up. Univariate Cox proportional hazards models of PFS and OS were fit and Kaplan-Meier plots were developed to estimate the impact of variables of interest on survival. Results Out of 259 patients undergoing ASCT for DLBCL, 43 received > 1 salvage treatment, the median age was 51 years and 23 patients were male. Twenty patients had stage III/IV disease at diagnosis. The median time to relapse from the time of diagnosis was 9.3 months, and 42% of patients experienced a relapse > 12 months after diagnosis. Twenty-six patients (60%) received radiation as one of their salvage therapies, 25 patients (58%) received R-ICE as their first salvage therapy and 10 (23%) patients received R-ICE as their second salvage treatment. All patients received either 2 (n=39) or 3 (n=4) salvage therapies before ASCT, and the response to the initial salvage therapy received was CR in 4 patients, PR in 14 patients, SD in 1 patient, and PD in 14 patients, with initial response to salvage therapy missing in 10 patients. The median PFS for all patients was 15.9 months and the median OS was 57.2 months (Figure 1a). Receipt of radiation and having disease sensitive to treatment at the time of ASCT were the only factors associated with prolonged PFS and OS. Median PFS has not been achieved in patients who received radiation while patients who did not receive radiation had a median PFS of 4.2 months (HR = 0.36, p = 0.014; Figure 1b). Patients who had a chemo sensitive disease status at transplant had a median PFS of 22.6 months; however, patients with refractory disease at transplant only achieved a median PFS of 3.6 months (HR = 0.30, p=0.008). Remaining factors including conditioning regimen, time to relapse, and number of salvage therapies were not significantly associated with PFS or OS. Conclusions ASCT can result in prolonged PFS/OS in patients requiring > 1 salvage therapy especially in the case of sensitive disease. Radiation as an additional line of therapy is associated with improved PFS/OS, suggesting this can be included to induce remission in patients who fail to achieve CR with initial salvage treatment. While uncommon, patients with chemo-refractory disease can also have durable survival and should not be excluded from transplant. Figure 1a Progression-free survival for all patients with DLBCL receiving > 1 salvage therapy. Figure 1a. Progression-free survival for all patients with DLBCL receiving > 1 salvage therapy. Figure 1b Progression-free survival for all patients with DLBCL receiving > 1 salvage therapy based on receipt of radiation therapy. Figure 1b. Progression-free survival for all patients with DLBCL receiving > 1 salvage therapy based on receipt of radiation therapy. Disclosures: Calzada: Seattle Genetics: Research Funding. Flowers:Spectrum, Janssen, Infinity, AbbVie, Acerta, Pharmacyclics, TG Therapeutics: Research Funding; Celgene Corporation: Consultancy, Honoraria; Optum Rx, Seattle Genetics, Genentech/Roche: Consultancy; Gilead: Consultancy, Research Funding; Millennium: Consultancy, Research Funding; Seattle Genetics: Research Funding. Cohen:Bristol-Myers Squibb: Research Funding; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Infinity: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Millennium/Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.


  • Deferred treatment as a viable option for selected patients with mantle cell lymphoma.

    by Oscar Calzada, Jeffrey M. Switchenko, Joseph J. Maly, Kristie A. Blum, Natalie Sophia Grover, Stephanie Mathews, Steven I. Park, Max J Gordon, Alexey Valeryevich Danilov, Christopher Flowers, et al.

    7567 Background: While mantle cell lymphoma (MCL) has historically been treated at the time of diagnosis, we recently reported a national cohort analysis which identified a subset of patients who can safely defer therapy (Cohen et. al, ASH 2015), validating previously reported single-center findings (Martin et al, JCO 2009). We conducted a multicenter analysis of MCL patients with additional clinical data to better describe the role of deferred therapy in MCL. Methods: Patients ≥ 18 years old who received initial treatment for newly diagnosed MCL between 1995-2015 at one of four academic sites were included. Deferred therapy was defined as receipt of first treatment > 90 days following diagnosis. We identified variables associated with receipt of deferred therapy and evaluated the impact of deferred therapy, demographic factors and MIPI components on progression-free (PFS) and overall survival (OS) in multivariable regression models. Results: Of 356 patients, 71 (20%) received deferred therapy with a median time to treatment for this group of 234 days. Among all patients, the median age at diagnosis was 62 years, 72% were male, 95% were stage III/IV, and 32% presented with B symptoms. Patients receiving deferred therapy were more likely to have an ECOG performance status of 0 (68% vs 49% p = 0.009), lack B symptoms (83% vs 65% p = 0.004) and have normal LDH levels at diagnosis (87% vs 57% p < 0.001). Patients receiving immediate treatment more commonly had bone marrow involvement (84% vs 71% p = 0.016) and splenomegaly (58% vs 41% p = 0.015). In multivariable analysis presence of complex karyotype (CK; ≥ 3 chromosomal abnormalities) was the only significant predictor of inferior OS (HR 3.17, 95% CI 1.69-5.95). Deferred therapy was not associated with differences in OS (HR 0.64: 95% CI 0.30-1.33, p = 0.228), and there was no significant difference in frequency of a CK between the deferred and immediate therapy groups (p = 0.3). Conclusions: This retrospective, multi-center cohort analysis validates prior findings that deferred therapy may be a safe option for a subgroup of MCL patients. Future studies are needed to better identify suitable candidates for deferred therapy.


  • Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL).

    by Narendranath Epperla, Mehdi Hamadani, Kwang Woo Ahn, Eunhye Oak, Amanda F. Cashen, Abraham Sebastian Kanate, Oscar Calzada, Zachary Luke Farmer, Michael Tallarico, Chadi Nabhan, et al.

    7544 Background: Ibrutinib (IB) has shown significant activity in R/R MCL in prospective studies, but less is known about its “real world” activity. Moreover factors predicting IB failure, impact of prior transplantation (HCT) on IB’s efficacy and patient (pt) outcomes following IB failure warrant further investigation. Methods: We performed a multicenter retrospective study of R/R MCL pts receiving IB between Nov 2013 and Dec 2015. Pts achieving a CR or PR with IB were considered responders. The primary aim was to evaluate predictive factors for IB response, while the secondary aims were to examine predictors for OS & PFS following IB therapy, impact of prior HCT on IB therapy and assessment of pt outcomes post IB failure. Results: 97 pts met study inclusion criteria. 62 pts (64%) achieved a CR/PR with IB, with a median duration of response (DOR) of 9 mo. None of the tested variables (Table) were predictive of IB response. Achieving CR/PR with IB (HR = 0.1), low MIPI (HR = 0.28) and pts without primary refractory disease (HR = 0.15) were predictors of better PFS, while IB response (HR = 0.13) and ECOG PS ≤ 1 (HR = 0.14) were predictors of better OS. IB response rate (RR) in pts without prior HCT, with prior autoHCT and with prior alloHCT was 65%, 66% & 64% respectively. Their median PFS & OS (in mo) in similar order were 10 vs 6 vs 4, and 13 vs 9.5 vs 8 respectively. After IB failure, the median OS was 2 mo. The RR to bortezomib (n = 9), lenalidomide (n = 10) & bendamustine (n = 6) use after IB failure was 30%, 20% & 50% respectively. Median DOR (in mo) in similar order was 7.4, 5.5 and 3 respectively. Conclusions: No clinical factors including types of prior therapies predicted response to IB therapy. In this large real world analysis, durability of IB response (9 mo) is shorter than previously reported. Pts failing IB have poor outcome and this represents an area of urgent unmet need.